Flu vaccine production Strains and protection

Date unknown

Ahead of the French vaccination campaign scheduled for October 13, Anne-Christine Roth visits a production facility with millions of ready syringes and Lyon's National Reference Centre. Sanofi's Pierre Caillaud describes WHO's February selection from surveillance data; the report names this year's Missouri, Darwin and Tokyo strains. Lucie Robin and Antonin Bal describe testing patient samples and vaccine neutralization, including an encouraging Toulon result. Mutations can reduce effectiveness and composition changes generally wait for the next season. The report gives variable effectiveness, lower protection in seniors, Imad Kansau's emphasis on preventing severe illness and two higher-dose vaccines for people over 65.

France 2 visits a Sanofi production facility with millions of 2026–27 influenza-vaccine syringes ready for pharmacy delivery. This year's cocktail uses the named Missouri, Darwin and Tokyo strains. Its accompanying Lyon laboratory account tests vaccine neutralization of circulating patient samples, including an encouraging Toulon result, while explaining mutation risks and why a composition update waits for another season. Variable effectiveness and the clinician's severe-illness prevention explanation remain qualified; the October 13 campaign is still prospective.